Chimeric antigen receptor (CAR)-T cells are a promising cancer therapy that are made from the patient's own T cells, which ...

T-cell therapy for rheumatologic disease is now expanding out of academe into the commercial space, with encouraging new data ...

T cells are a promising cancer therapy that are made from the patient's own T cells, which are reprogrammed to fight their ...

The phase 1b trial’s primary endpoints are the occurrence of adverse events, including dose-limiting toxicities, and the ...

In modern immunotherapy, modified immune cells are introduced into the body to attack tumors and other targets. Researchers ...

Johnson & Johnson said the first clinical data from its ongoing Phase 1b study of JNJ-4496, a chimeric antigen receptor T-cell therapy, shows encouraging potential in treating large B-cell lymphoma, ...

T cells are the immune system’s frontline fighters. When they detect danger, they rapidly multiply and transform into ...

To assess T-cell-induced morphological changes, each organoid was segmented in the transmitted light (TL) channel using a ...

Johnson & Johnson (NYSE: JNJ) announced today the first clinical data from an ongoing Phase 1b study for JNJ-90014496 (JNJ-4496), an investigational dual-targeting anti-CD19/CD20 bispecific autologous ...

CAR-T cells are specialized immune cells genetically modified to recognize and attack cancer cells. Researchers at Nagoya ...

A Gilead Sciences-backed therapy made with a patient's own white blood cells shrank tumors in 62% of patients with recurrent ...

T-cell therapy has shown remarkable clinical efficacy in haematological malignancies, currently representing a well ...